Proactiveinvestors recommends
Additional Information
Market: TSXV
Sector: Pharmaceuticals
EPIC: MDG
Medicago
www.medicago.com/en

Medicago is developing VLP vaccines to protect against H5N1 pandemic influenza, using a transient expression system which produces recombinant vaccine antigens in non-transgenic plants.

Full Medicago profile here
Pdf

Medicago to collaborate on multi-million US govt' grant for avian flu vaccine

11th Jan 2011, 2:24 pm
Medicago to collaborate on multi-million US govt' grant for avian flu vaccine

Biotech company Medicago (TSX: MDG) announced Tuesday that it was selected to collaborate with the Infectious Disease Research Institute (IDRI) on a multimillion dollar grant from the US Department of Defense, which will be used for the development of an avian flu vaccine.

The grant, awarded to IDRI by the US Dept's Defense Advanced Research Projects Agency (DARPA), will be used for a phase I clinical trial that will combine Medicago's plant-made H5 vaccine with IDRI's vaccine modifier technology, as well as a micro needle delivery device.

The idea behind the project is to create a single dose vaccine that can be produced, distributed and administered quickly in the case of a pandemic. Medicago's plant-based vaccine technology has been proven to produce emerging strains faster than conventional egg and cell-based technologies.

"This research collaboration may provide unique solutions that make vaccination against Influenza pandemics not only faster but with minimal dosing and greater ease of application," said president and CEO of Medicago, Andy Sheldon.

"We continue to advance the clinical development of our H5 avian flu vaccine and expect to have Phase II interim results within the coming weeks."

IDRI is a Seattle-based not-for-profit organization that looks to develop products to prevent and treat infectious diseases of poverty.

No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.